ENGLEWOOD CLIFFS, N.J., Oct. 16 /PRNewswire-FirstCall/ -- EpiCept Corporation announced today that Jack Talley, President and CEO, will present at the BIO InvestorForum Conference on Thursday, October 19th at 11:40am PDT in the Sea Cliff room. The conference will be held at The Palace Hotel in San Francisco.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )
Mr. Talley will be presenting a summary of the broad range of clinical portfolio product candidates at EpiCept for the treatment of pain and cancer, as well as data concerning the company's recent filing in Europe for a marketing authorization application (MAA) for Ceplene, its novel compound for the treatment of acute myeloid leukemia.
The presentation will be webcast live at:
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=EPCT&item_id=1400386
A replay of the webcast will be available one hour after the presentation and will be accessible for one year.
About EpiCept Corporation
EpiCept is an emerging specialty pharmaceutical company focused on unmet needs in the treatment of pain and cancer. The Company has a staged portfolio of product candidates with several pain therapies in late-stage clinical trials, and Ceplene, its lead oncology product candidate for the treatment of AML. EpiCept is based in New Jersey, and the Company's research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the clinical and regulatory development and potential commercialization of Ceplene, the efficacy, safety, and intended utilization of the Company's product candidates, the conduct and results of future clinical trials, the sufficiency of the Company's existing capital resources, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risks that Ceplene is not approved in the European Union, the Company is unable to find a suitable partner for the commercialization of Ceplene if it is approved, Ceplene does not achieve market acceptance, and the Company or its partners' commercialization efforts for Ceplene are not effective, the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that the Company will not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in the Company's periodic reports and other filings with the SEC.
EPCT-GEN
Photo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGOEpiCept CorporationCONTACT: Robert W. Cook of EpiCept Corporation, +1-201-894-8980,rcook@epicept.com; or Francesca T. DeVellis of Feinstein Kean Healthcare,+1-617-577-8110, francesca.devellis@fkhealth.com
Web site: http://www.epicept.com/
